Reversal of pancreatitis-induced pain by an orally available, small molecule interleukin-6 receptor antagonist a b s t r a c t Pancreatic pain resulting from chronic inflammation of the pancreas is often intractable and clinically difficult to manage with available analgesics reflecting the need for more effective therapies. The mechanisms underlying pancreatitis pain are not well understood. Here, the possibility that interleukin-6 (IL-6) may promote pancreatitis pain was investigated with TB-2-081 (3-O-formyl-20R,21-epoxyresibufogenin, EBRF), a small molecule IL-6 receptor antagonist that was semi-synthetically derived from natural sources. The potential activity and mechanism of TB-2-081 were investigated following the induction of persistent pancreatitis using dibutyltin dichloride (DBTC) in rats. TB-2-081 displaces the binding of IL-6 to the human recombinant soluble IL-6 receptor with apparent high affinity and inhibits IL-6 mediated cell growth. Systemic or oral, but not intrathecal, administration of TB-2-081 reversed DBTC-induced abdominal hypersensitivity in a dose-and time-dependent manner. IL-6 levels were significantly up-regulated in the dorsal root ganglia (DRG) of rats with pancreatitis on day 6 after DBTC injection. IL-6-enhanced capsaicin-evoked release of calcitonin gene-related peptide from cultured DRG neurons was blocked by TB-2-081. Our data demonstrate that TB-2-081 acts as a systemically available and orally active small molecule IL-6 receptor antagonist. TB-2-081 effectively reduces pancreatitisinduced pain through peripheral mechanisms that are likely due to (a) increased expression of IL-6 in the DRG and (b) IL-6-mediated sensitization of nociceptive neurons. The activity of TB-2-081 implicates an important role for IL-6 in sustaining pancreatitis pain. Strategies targeting IL-6 actions through small molecule antagonists may offer novel approaches to improve the therapy of chronic pancreatitis and other chronic pain states.
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Introduction
Chronic pancreatitis is a continuous inflammatory disease of the pancreas characterized by irreversible morphological changes that typically cause pain and permanent loss of function. Pain is the most challenging and debilitating symptom associated with this condition. Initial treatment is generally conservative and includes non-opioid analgesics, followed by opioids [9] . However, a subgroup of patients ultimately develop severe, incapacitating epigastric pain that markedly reduces their quality of life [34] . Conservative pain control efforts in these patients can lead to a vicious cycle of increasing need for narcotic analgesics and significant unwanted side-effects including somnolence, mental confusion and gastrointestinal problems [3] as well as potential for addiction. Therefore, there is a high and unmet need for novel therapies for the treatment of pancreatitis-induced pain.
The pleiotropic cytokine, interleukin-6 (IL-6) is markedly upregulated during various pathological conditions and is generally associated with increased pain and hyperalgesia. Most experimental studies report pro-inflammatory and pro-nociceptive roles for IL-6. Intramuscular, intradermal, intracerebroventricular, or intrathecal injection of IL-6 induces allodynia or hyperalgesia in rats [6, 30] Abbreviations: CGRP, calcitonin gene-related peptide; DBTC, dibutyltin dichloride; DRG, dorsal root ganglia; IL-6R, interleukin-6 receptor; TB-2-081, 3-O-formyl-20R,21-epoxyresibufogenin.
